Stock Library / TGTX

TGTX Unclassified Latest YouTube: Q2 2026 Published 2026-08-03

TGTX

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

TG Therapeutics (TGTX): Revenue +70% And Operating Income FELL. Is TGTX a Buy?

Published 2026-08-03

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-03

Podcast available

Yes

Current price

$46.17

-5.63 (-10.87%)

Trailing / Forward P/E

16.14x

Forward: 14.28x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

69.6%

Earnings: 300.0%

Margins

17.0% op

Gross: 83.1% · Net: 66.0%

Balance sheet

5.81x current

Debt / Equity: 129.2

52-week range / Beta

$25.28 - $59.30

Beta: 1.67

Analyst target

$68.43

Upside: 48.2%

Cash / shareholder return

-0.43% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 11.22x

Return on equity: 112.6%

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Price chart

Market context for TGTX

Competitive view

TGTX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

TGTX latest YouTube video thumbnail

TGTX

TGTX

YouTube Spotify Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Danaher Corporation latest YouTube video thumbnail

Danaher Corporation

DHR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

TGTX

$7.07B

TGTX

SSNC

$18.63B

SS&C Technologies Holdings Inc.

DHR

$138.84B

Danaher Corporation

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

TGTX

16.1x

TGTX

SSNC

22.8x

SS&C Technologies Holdings Inc.

DHR

35.1x

Danaher Corporation

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

TGTX

14.3x

TGTX

SSNC

10.3x

SS&C Technologies Holdings Inc.

DHR

21.2x

Danaher Corporation

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

TGTX

69.6%

TGTX

SSNC

10.3%

SS&C Technologies Holdings Inc.

DHR

5.5%

Danaher Corporation

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

TGTX

300.0%

TGTX

SSNC

34.7%

SS&C Technologies Holdings Inc.

DHR

59.7%

Danaher Corporation

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

TGTX

17.0%

TGTX

SSNC

24.6%

SS&C Technologies Holdings Inc.

DHR

19.8%

Danaher Corporation

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

TGTX

83.1%

TGTX

SSNC

48.1%

SS&C Technologies Holdings Inc.

DHR

58.8%

Danaher Corporation

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

TGTX

66.0%

TGTX

SSNC

13.2%

SS&C Technologies Holdings Inc.

DHR

15.9%

Danaher Corporation

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

TGTX

112.6%

TGTX

SSNC

12.6%

SS&C Technologies Holdings Inc.

DHR

7.6%

Danaher Corporation

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

TGTX

-0.4%

TGTX

SSNC

7.0%

SS&C Technologies Holdings Inc.

DHR

3.1%

Danaher Corporation

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

TGTX

129.23x

TGTX

SSNC

115.90x

SS&C Technologies Holdings Inc.

DHR

52.97x

Danaher Corporation

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

TGTX

5.81x

TGTX

SSNC

1.06x

SS&C Technologies Holdings Inc.

DHR

1.65x

Danaher Corporation

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

TGTX

1.67

TGTX

SSNC

1.09

SS&C Technologies Holdings Inc.

DHR

0.80

Danaher Corporation

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

TGTX

—

TGTX

SSNC

0.7%

SS&C Technologies Holdings Inc.

DHR

0.7%

Danaher Corporation

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

TGTX

48.2%

TGTX

SSNC

16.3%

SS&C Technologies Holdings Inc.

DHR

15.4%

Danaher Corporation

Related research

Non-quarter videos featuring TGTX

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-03

TGTX: Revenue +70% But Profit FELL #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for TGTX

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-03

Published youtube podcast complete

TG Therapeutics (TGTX): Revenue +70% And Operating Income FELL. Is TGTX a Buy?

Quarterly earnings-analysis entry for TGTX. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music